Monoclonal antibody-based therapies for microbial diseases

Carolyn Saylor, Ekaterina Dadachova, Arturo Casadevall

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

The monoclonal antibody (mAb) revolution that currently provides many new options for the treatment of neoplastic and inflammatory diseases has largely bypassed the field of infectious diseases. Only one mAb is licensed for use against an infectious disease, although there are many in various stages of development. This situation is peculiar given that serum therapy was one of the first effective treatments for microbial diseases and that specific antibodies have numerous antimicrobial properties. The underdevelopment and underutilization of mAb therapies for microbial diseases has various complex explanations that include the current availability of antimicrobial drugs, small markets, high costs and microbial antigenic variation. However, there are signs that the climate for mAb therapeutics in infectious diseases is changing given increasing antibiotic drug resistance, the emergence of new pathogenic microbes for which no therapy is available, and development of mAb cocktail formulations. Currently, the major hurdle for the widespread introduction of mAb therapies for microbial diseases is economic, given the high costs of immunoglobulin preparations and relatively small markets. Despite these obstacles there are numerous opportunities for mAb development against microbial diseases and the development of radioimmunotherapy provides new options for enhancing the magic bullet. Hence, there is cautious optimism that the years ahead will see more mAbs in clinical use against microbial diseases.

Original languageEnglish (US)
JournalVaccine
Volume27
Issue numberSUPPL.6
DOIs
StatePublished - Dec 30 2009

Fingerprint

monoclonal antibodies
Monoclonal Antibodies
therapeutics
infectious diseases
Communicable Diseases
Therapeutics
markets
Radioimmunotherapy
Costs and Cost Analysis
Antigenic Variation
antigenic variation
Magic
anti-infective properties
Microbial Drug Resistance
Climate
Drug Resistance
antibiotic resistance
immunoglobulins
Immunoglobulins
anti-infective agents

Keywords

  • Infectious disease
  • Monoclonal antibody
  • Therapeutics

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Monoclonal antibody-based therapies for microbial diseases. / Saylor, Carolyn; Dadachova, Ekaterina; Casadevall, Arturo.

In: Vaccine, Vol. 27, No. SUPPL.6, 30.12.2009.

Research output: Contribution to journalArticle

Saylor, C, Dadachova, E & Casadevall, A 2009, 'Monoclonal antibody-based therapies for microbial diseases', Vaccine, vol. 27, no. SUPPL.6. https://doi.org/10.1016/j.vaccine.2009.09.105
Saylor, Carolyn ; Dadachova, Ekaterina ; Casadevall, Arturo. / Monoclonal antibody-based therapies for microbial diseases. In: Vaccine. 2009 ; Vol. 27, No. SUPPL.6.
@article{f67927acf132452081c05f894ef14ad2,
title = "Monoclonal antibody-based therapies for microbial diseases",
abstract = "The monoclonal antibody (mAb) revolution that currently provides many new options for the treatment of neoplastic and inflammatory diseases has largely bypassed the field of infectious diseases. Only one mAb is licensed for use against an infectious disease, although there are many in various stages of development. This situation is peculiar given that serum therapy was one of the first effective treatments for microbial diseases and that specific antibodies have numerous antimicrobial properties. The underdevelopment and underutilization of mAb therapies for microbial diseases has various complex explanations that include the current availability of antimicrobial drugs, small markets, high costs and microbial antigenic variation. However, there are signs that the climate for mAb therapeutics in infectious diseases is changing given increasing antibiotic drug resistance, the emergence of new pathogenic microbes for which no therapy is available, and development of mAb cocktail formulations. Currently, the major hurdle for the widespread introduction of mAb therapies for microbial diseases is economic, given the high costs of immunoglobulin preparations and relatively small markets. Despite these obstacles there are numerous opportunities for mAb development against microbial diseases and the development of radioimmunotherapy provides new options for enhancing the magic bullet. Hence, there is cautious optimism that the years ahead will see more mAbs in clinical use against microbial diseases.",
keywords = "Infectious disease, Monoclonal antibody, Therapeutics",
author = "Carolyn Saylor and Ekaterina Dadachova and Arturo Casadevall",
year = "2009",
month = "12",
day = "30",
doi = "10.1016/j.vaccine.2009.09.105",
language = "English (US)",
volume = "27",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "SUPPL.6",

}

TY - JOUR

T1 - Monoclonal antibody-based therapies for microbial diseases

AU - Saylor, Carolyn

AU - Dadachova, Ekaterina

AU - Casadevall, Arturo

PY - 2009/12/30

Y1 - 2009/12/30

N2 - The monoclonal antibody (mAb) revolution that currently provides many new options for the treatment of neoplastic and inflammatory diseases has largely bypassed the field of infectious diseases. Only one mAb is licensed for use against an infectious disease, although there are many in various stages of development. This situation is peculiar given that serum therapy was one of the first effective treatments for microbial diseases and that specific antibodies have numerous antimicrobial properties. The underdevelopment and underutilization of mAb therapies for microbial diseases has various complex explanations that include the current availability of antimicrobial drugs, small markets, high costs and microbial antigenic variation. However, there are signs that the climate for mAb therapeutics in infectious diseases is changing given increasing antibiotic drug resistance, the emergence of new pathogenic microbes for which no therapy is available, and development of mAb cocktail formulations. Currently, the major hurdle for the widespread introduction of mAb therapies for microbial diseases is economic, given the high costs of immunoglobulin preparations and relatively small markets. Despite these obstacles there are numerous opportunities for mAb development against microbial diseases and the development of radioimmunotherapy provides new options for enhancing the magic bullet. Hence, there is cautious optimism that the years ahead will see more mAbs in clinical use against microbial diseases.

AB - The monoclonal antibody (mAb) revolution that currently provides many new options for the treatment of neoplastic and inflammatory diseases has largely bypassed the field of infectious diseases. Only one mAb is licensed for use against an infectious disease, although there are many in various stages of development. This situation is peculiar given that serum therapy was one of the first effective treatments for microbial diseases and that specific antibodies have numerous antimicrobial properties. The underdevelopment and underutilization of mAb therapies for microbial diseases has various complex explanations that include the current availability of antimicrobial drugs, small markets, high costs and microbial antigenic variation. However, there are signs that the climate for mAb therapeutics in infectious diseases is changing given increasing antibiotic drug resistance, the emergence of new pathogenic microbes for which no therapy is available, and development of mAb cocktail formulations. Currently, the major hurdle for the widespread introduction of mAb therapies for microbial diseases is economic, given the high costs of immunoglobulin preparations and relatively small markets. Despite these obstacles there are numerous opportunities for mAb development against microbial diseases and the development of radioimmunotherapy provides new options for enhancing the magic bullet. Hence, there is cautious optimism that the years ahead will see more mAbs in clinical use against microbial diseases.

KW - Infectious disease

KW - Monoclonal antibody

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=72049112028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72049112028&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2009.09.105

DO - 10.1016/j.vaccine.2009.09.105

M3 - Article

VL - 27

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - SUPPL.6

ER -